Live Breaking News & Updates on Neximmune Company Profile Get Rating|Page 1

Stay updated with breaking news from Neximmune company profile get rating. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Zacks Investment Research Lowers NexImmune (NASDAQ:NEXI) to Hold

NexImmune (NASDAQ:NEXI – Get Rating) was downgraded by Zacks Investment Research from a “buy” rating to a “hold” rating in a research note issued to investors on Friday, Zacks.com reports. According to Zacks, “NexImmune Inc. is a clinical-stage biotechnology company. It engages in developing a novel approach to immunotherapy designed to employ the body’s own […] ....

New York , United States , Raymond James , Kristi Jones , York State Common Retirement Fund , Zacks Investment Research , Neximmune Company Profile Get Rating , Wells Fargo Company , Cantor Fitzgerald , Neximmune Inc , Smith Salley Associates , Citigroup Inc , Royal Bank , Get Rating , Director Grant Verstandig , Immune Company Profile , Artificial Immune Modulation , Nasdaq Nexi ,

NexImmune, Inc. (NASDAQ:NEXI) Short Interest Up 46.6% in March

NexImmune, Inc. (NASDAQ:NEXI – Get Rating) saw a large increase in short interest in the month of March. As of March 31st, there was short interest totalling 865,000 shares, an increase of 46.6% from the March 15th total of 590,000 shares. Based on an average daily volume of 191,100 shares, the days-to-cover ratio is presently […] ....

New York , United States , Thomson Reuter , Raymond James , Solj Barer , Morgan Stanley , York State Common Retirement Fund , Zacks Investment Research , Neximmune Company Profile Get Rating , Wells Fargo Company , Cantor Fitzgerald , Neximmune Inc , Citigroup Inc , Royal Bank , Get Rating , Director Sol , Director Grant Verstandig , Wells Fargo , Immune Company Profile , Artificial Immune Modulation , Nasdaq Nexi ,

NexImmune (NASDAQ:NEXI) PT Raised to $7.00 at Barclays

NexImmune (NASDAQ:NEXI – Get Rating) had its target price boosted by Barclays from $4.00 to $7.00 in a report issued on Friday, The Fly reports. They currently have an overweight rating on the stock. Several other equities analysts have also recently weighed in on the stock. Cantor Fitzgerald reiterated an overweight rating on shares of […] ....

New York , United States , Raymond James , Solj Barer , Kristi Jones , Geode Capital Management , Zacks Investment Research , Blackrock Inc , First Manhattan Co , Neximmune Company Profile Get Rating , Cantor Fitzgerald , Neximmune Inc , Get Rating , Director Sol , Capital Management , Street Corp , Immune Company Profile , Artificial Immune Modulation , Nasdaq Nexi , Boost Price Target , Barclays Plc ,

Insider Buying: NexImmune, Inc. (NASDAQ:NEXI) Director Acquires $71,376.08 in Stock

NexImmune, Inc. (NASDAQ:NEXI – Get Rating) Director Grant Verstandig purchased 18,983 shares of NexImmune stock in a transaction that occurred on Monday, March 28th. The shares were bought at an average price of $3.76 per share, for a total transaction of $71,376.08. The transaction was disclosed in a legal filing with the Securities & Exchange […] ....

New York , United States , Raymond James , Morgan Stanley , York State Common Retirement Fund , Securities Exchange Commission , Zacks Investment Research , Neximmune Company Profile Get Rating , Cantor Fitzgerald , Wells Fargo Company , Neximmune Inc , Citigroup Inc , Royal Bank , Get Rating , Director Grant Verstandig , Exchange Commission , Grant Verstandig , Wells Fargo , Immune Company Profile , Artificial Immune Modulation , Nasdaq Nexi , Insider Trading , Nsider Trades ,